Currently, NVO's 12-month EPS stands at 26.23 DKK, according to the most recent financial reports. Novo Nordisk's earnings per share in 2025 was reported at 23.06 DKK, marking a rise from 22.67 DKK in 2024. NVO recorded an EPS of 4.74 DKK for the quarterly period ending on Jun 30, 2026.
In 2025, Novo Nordisk's earnings per share was 23.06 DKK, a rise of 1.7% from 22.67 DKK in 2024. The quarterly earnings per share for the period ending Jun 30, 2026, was 4.74 DKK, showing a 20.5% decline compared to the same quarter last year. The trailing twelve months EPS for NVO is 26.23 DKK as of June 2026. Novo Nordisk's full-year EPS for 2024 was 22.67 DKK, a 21.4% rise compared to the previous year.
Novo Nordisk has recorded a decline in earnings per share of 20.5% in the past 12 months (YoY, quarterly). Across the past three years, the company had an average EPS annual growth rate of 23.4% per year. Novo Nordisk had an average annual EPS growth of 20.7% in the last five years. When assessed over a ten-year period, NVO's average EPS annual growth was 13%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| NVO Novo Nordisk | 11.46 | 1.7% | 23.4% | 20.7% |
| BMY Bristol-Myers Squibb Company | 14.03 | 178.7% | 5.3% | N/A |
| REGN Regeneron Pharmaceuticals Inc | 19.16 | 5.3% | 2.1% | 5.7% |
| NVS Novartis AG | 22.65 | 21.8% | 31.2% | 15.2% |
| AZN Astrazeneca plc | 23.21 | 45.4% | 46% | 22% |
| AMGN AMGEN Inc | 25.6 | 88.1% | 5.6% | 2.9% |
| LLY Lilly(Eli) & Company | 39.55 | 95.6% | 49.2% | 27.5% |
| MRK Merck & Co Inc | 106.96 | 8% | 8.4% | 21.2% |
| GILD Gilead Sciences Inc | N/A | 1,700% | 23.2% | 132.8% |
All data is based on quarterly TTM periods, unless otherwise specified.